SCHEMBL14280676

SCHEMBL14280676

Clc1ccc2c(C3CCN(Cc4cccc5ccccc45)CC3)cn(Cc3ccccc3)c2c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.52
OPRK1 P41145 4/20 0.52
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
HRH2 P25021 5/20 0.48
ACHE P22303 1/20 0.47
HTR2A P28223 2/20 0.47
HTR2C P28335 2/20 0.47
HTR2B P41595 2/20 0.47
OPRL1 P41146 3/20 0.47
BCHE P06276 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
DRD2 P14416 2/20 0.43
HTR6 P50406 2/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14280678 0.88 OPRM1 (0.44) OPRM1OPRK1MEN1KMT2AHRH2
SCHEMBL14280679 0.80 CNR1 (0.48) OPRM1OPRK1HRH2ACHEHTR2A
SCHEMBL4882103 0.77 HTR6 (0.50) OPRM1OPRK1OPRL1HTR6CNR1
SCHEMBL14280675 0.77 OPRL1 (0.55) OPRM1OPRK1HRH2HTR2AHTR2C
SCHEMBL28425145 0.71 DRD2 (0.65) OPRM1OPRK1MEN1KMT2AACHE
SCHEMBL15800713 0.71 ACHE (0.62) MEN1KMT2AACHEOPRL1SIGMAR1
SCHEMBL5419830 0.69 CYP19A1 (0.52) KMT2AHRH2HTR2AHTR6CNR2
SCHEMBL22491533 0.69 HTR6 (0.54) MEN1KMT2AHRH2HTR2AHTR2C
SCHEMBL25322972 0.69 KCNA3 (0.44) MEN1KMT2ACNR1CNR2
SCHEMBL14280680 0.69 OPRM1 (1.00) OPRM1OPRK1MEN1KMT2AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015214-A1 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-01-17 US disclosed
US-20080015214-A1 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015214-A1 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS OGFRL1, OPRL1, ORMDL3 OPRM1 11/4885OPRK1 5/4885MEN1 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.